Papillary Thyroid Carcinoma During Etanercept Therapy in a Patient with Psoriatic Arthritis
Science Journal of Clinical Medicine
Volume 4, Issue 5, September 2015, Pages: 93-95
Received: Aug. 13, 2015;
Accepted: Aug. 24, 2015;
Published: Sep. 2, 2015
Views 3557 Downloads 89
Ilker Ilhanli, Department of Physical Medicine and Rehabilitation, School of Medicine, Giresun University, Giresun, Turkey
Necip Guder, Physical Medicine and Rehabilitation State Hospital, Giresun, Turkey
Potential for developing malignancies with Tumor necrosis alpha blockers (Anti-TNFα) in romatologic diseases is an important question in our minds, contrary to the proved efficacy of them. To our knowledge, yet no case report has been established about papillary thyroid carcinoma during etanercept therapy for psoriatic arthritis. Here we reported a patient who was diagnosed as papillary thyroid carcinoma while she was using etanercept for psoriatic arthritis. She had medical history for familial trait of carcinoma. Radioactive iodine therapy was administered after the surgery. We preferred to stop etanercept therapy and there was no increase in clinical and laboratory disease activity.
Papillary Thyroid Carcinoma During Etanercept Therapy in a Patient with Psoriatic Arthritis, Science Journal of Clinical Medicine.
Vol. 4, No. 5,
2015, pp. 93-95.
Georgakopoulou EA, Andreadis D, Arvanitidis E, Loumou P. Biologic agents and oral diseases--an update on clinical applications. Acta dermatovenerologica Croatica: ADC. 2013; 21: 24-34.
Tobiás B, Halászlaki C, Balla B et al. Genetic Alterations in Hungarian Patients with Papillary Thyroid Cancer. Pathol Oncol Res. 2015 Aug 11. [Epub ahead of print]
Nikiforov YE. Thyroid carcinoma: molecular pathways and yherapeutic targets. Mod Pathol. 2008; 21(2):37-43.
Mitsiades CS, Poulaki V, Mitsiades N. The role of apoptosis-inducing receptors of the tumor necrosis factor family in thyroid cancer. J. Endocrinol. 2003 Aug; 178(2): 205-216.
Tsatsoulis A. The role of apoptosis in thyroid disease. Minerva Med. 2002; 93(3): 169-180.
Gelfand JM, Berlin J, Van Voorhees A, Margolis DJ. Lymphoma rates are low but increased in patients with psoriasis: results from a population based cohort study in the United Kingdom. Arch Dermatol. 2003; 139: 1425-1429.
Margolis D, Bilker W, Hennessy S, Vittorio C, Santanna J, Strom BL. The risk of malignancy associated with psoriasis. Arch Dermatol. 2001; 137:778-783.
Wolfe F, Michaud K. The association of new cases of cancer with biologic therapy. Arthritis Rheum. 2006; 54: 549.
Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and metaanalysis of rare harmful effects in randomized controlled trials. J Am Med Assoc. 2006; 295: 2275-2285.
Okada SK, Siegel JN. Risk of serious infections and malignancies with antiTNF antibody therapy in rheumatoid arthritis. J Am Med Assoc. 2006; 296: 2201-2202.
Diak P, Siegel J, La Grenade L, Choi L, Lemery S, McMahon A. Tumor necrosis factor α blockers and malignancy in children: Forty-eight cases reported to the food and drug administration. Arthritis & Rheumatism. 2010; 62(8): 2517-2524
Lee JJ, Mann JA, Blauvelt A. Papillary thyroid carcinoma in a patient with severe psoriasis receiving adalimumab. J Am Acad Dermatol. 2011; 64(5): 999-1000.
Kimball AB, Schenfeld J, Accortt NA, Anthony MS, Rothman KJ, Pariser D. Cohort Study of Malignancies and Hospitalised Infectious Events in Treated and Untreated Patients with Psoriasis and a General Population in the United States. Br J Dermatol. 2015 Aug 12. doi: 10.1111/bjd.14068. [Epub ahead of print].